Drinkable supplement for hair loss in women on weight-loss drugs
Part of Skin clinical trials.
This trial tests if a special drinkable supplement can help prevent or reduce hair loss in women who are taking a GLP-1 or GIP receptor agonist (a type of weight-loss or diabetes medication). The study looks for women who have just started this medication or have been on it for less than 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman over 35 years old.
- You have been taking a GLP-1 or GIP agonist (like Ozempic, Wegovy, Mounjaro) for less than 3 months, or you are about to start.
- You have no known allergies to any ingredients in the study supplement.
- You do not have certain scalp conditions (like scarring alopecia, psoriasis, or severe dandruff).
- Your hair loss is not caused by an underlying medical condition (like thyroid disease, anemia, or lupus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (DA-001) to reduce hair shedding and help hair grow back in people with telogen effluvium—a temporary hair loss condition. The treatment is applied directly to the scalp, and participants will be followed to see how well it works.
This study is testing whether a special dietary supplement can help women who are losing hair after using GLP-1 weight-loss drugs (like semaglutide or tirzepatide). If you are a woman aged 20-60 on a GLP-1 medication and have noticed increased hair shedding, you might be eligible to join.
This trial tests whether a combination of a dietary supplement and a topical serum can help women with thinning hair grow thicker, fuller hair. It's designed for women who have noticed mild to moderate hair thinning and want a non-invasive approach.
This study tests whether a dietary supplement helps hair growth in men with mild to moderate male pattern baldness. It lasts 6 months, and you will not know if you are getting the real supplement or a placebo.
This Phase 3 trial tests whether a 1 mg oral minoxidil pill helps improve hair thinning in women and checks its safety. If you match the study’s hair-loss pattern and can follow the visit and medication routine, you may be able to join.
This study tests a new medication (N1087) for female pattern hair loss in women aged 18 to 60. It aims to see if the treatment helps regrow hair and is safe.
Hear when a new Telogen Effluvium trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.